Biocon Gets USFDA Approval for Generic Heart Failure Drug
Biocon's subsidiary receives USFDA approval for generic Sacubitril/Valsartan Tablets, a medication used to treat chronic heart failure in adults and children.
Photograph: Kind courtesy Biocon
New Delhi, Sep 1 (PTI) Biotechnology firm Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure.
Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing.
Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.
The medicine is also used to treat paediatric patients over the age of one year.
The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.
Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing.
Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation.
The medicine is also used to treat paediatric patients over the age of one year.
The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 7.62 (+ 4.96)
- 103031030
- GTL Infrastructure
- 1.53 (+ 1.32)
- 21582832
- Guj. Toolroom Lt
- 1.72 (+ 3.61)
- 13450663
- Jaiprakash Power Ven
- 14.97 (+ 2.18)
- 13128177
- Standard Capital
- 0.56 ( -1.75)
- 13006780
MORE NEWS
© 2025 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback